In this episode of Post-Scrip, Henry introduces Douglas Braun, PharmaD, RPh, CPh, CSP. They discuss the upcoming "Impact of Inflation Reduction Act on Prescription drug costs, access and the financial impact of Medicare D reimbursement."
The implementation of the Inflation Reduction Act in 2024 has a significant impact on both pharmacies and patients. Patients covered under Medicare Part D will see potentially significant savings from capped insulin costs to major reductions in total out-of-pocket spending.
For patients receiving specialty medications, the IRA will be a huge relief from the financial toxicities that often face a patient and their access to affordable treatment. For pharmacies, it is a mixed bag of results. The reduction in out-of-pocket costs for patients can potentially allow patients to stay on therapy longer which can increase a pharmacy's revenue.
Join us at the 35th annual conference: Developments in Pharmacy Law Seminar , November 7-10, 2024 in Phoenix, Arizona
